Clinical trials: Peripheral T Cells Lymphoma (PTCL)
Peripheral T-Cell Lymphoma
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
The purpose of this study is to determine whether the treatment of Alemtuzumab in combination with CHOP(cyclophosphamide,doxorubicin,vincristine and prednisolone) are effective as first line treatment in patients with peripheral…
- Trial name
- NCT00441025
- Testing
- Alemtuzumab
- Where
- Thailand
- Volunteers
- 4 people
- Sponsor
- Mahidol University
Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic…
- Conditions
- Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02520791
- Testing
- Anti-ICOS Monoclonal Antibody MEDI-570, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 23 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral T Cell Lymphoma
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study.
- Trial name
- CRESCENDO (NCT06072131)
- Testing
- Belinostat Injection, Pralatrexate Injection, CHOP
- Where
- 58 sites in United States, Canada and 8 more
- Volunteers
- 504 people
- Sponsor
- Acrotech Biopharma Inc.
Peripheral T-Cell Lymphoma
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
This study will determine the maximum dose of KW-0761 administered intravenously that can be given safely in subjects with previously treated peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma(CTCL)and will see if it…
- Trial name
- NCT00888927
- Testing
- KW-0761
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
Phase 1b Safety and Efficacy Study of TRU-016
The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and idelalisib, or in combination with ibrutinib in…
- Trial name
- NCT01644253
- Testing
- 20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab
- Where
- 8 sites in United States
- Volunteers
- 87 people
- Sponsor
- Aptevo Therapeutics
Peripheral T-cell Lymphoma
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
The purpose of this study is to assess efficacy and safety of belinostat in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL), who failed at least one prior systemic therapy.
- Trial name
- PTCL (NCT00865969)
- Testing
- Belinostat
- Where
- 117 sites in United States, Belgium and 15 more
- Volunteers
- 129 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
PTCL, First Line Treatment
SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)
This is a single-arm, multicenter, Phase Ib/IIa study designed to explore the efficacy and safety of SHR2554 in combination with liposomal mitoxantrone for the treatment of patients with treatment-naive peripheral T-cell lymphoma…
- Trial name
- NCT07725705
- Testing
- SHR2554 combined with Liposomal Mitoxantrone
- Volunteers
- 44 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Peripheral T Cell Lymphoma
Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)
This study evaluates the efficacy and safety of Chidamide plus CHOP regimen for de novo PTCL patients.
- Trial name
- CHOP (NCT03268889)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Mature T-Cell and NK-Cell Neoplasm
Copanlisib and Gemcitabine in Relapsed/Refractory PTCL
COPGEM (Copanlisib and Gemcitabine)chemotherapy regimen is proposed as the salvage treatment for relapsed or refractory peripheral T-cell or NK/T-cell lymphomas in this study protocol, which would be expected to be feasible and…
- Trial name
- NCT03052933
- Testing
- Copanlisib, Gemcitabine
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Chonnam National University Hospital
PTCL, NK T-Cell Lymphoma
TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
This is a randomized, open-label, multicenter Phase III study evaluating the efficacy and safety of TR115, an EZH2 inhibitor, versus investigator's choice (chidamide, golidocitinib, mitoxantrone liposome, or gemcitabine) in…
- Trial name
- NCT07639879
- Testing
- TR115, Investigator's Choice
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Tarapeutics Science Inc.
PTCL, CTCL
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D)…
- Trial name
- NCT03240211
- Testing
- Pembrolizumab, Pralatrexate, Decitabine
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Virginia
Peripheral T-cell Lymphoma
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
This is single-arm phase I/II study designed to evaluate the safety and efficacy of golcadotinib in combination with the CHOP regimen for patients with newly diagnosed peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT06739265
- Testing
- Golidocitinib plus CHOP
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Peking Union Medical College Hospital
Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
- Conditions
- Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS
- Trial name
- NAVAL-1 (NCT05011058)
- Testing
- Nanatinostat in combination with valganciclovir
- Where
- 62 sites in United States, Australia and 12 more
- Volunteers
- 102 people
- Sponsor
- Viracta Therapeutics, Inc.
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Expanded Access to Tipifarnib
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
- Trial name
- Kuraoncology (NCT04809233)
- Testing
- Tipifarnib
- Sponsor
- Kura Oncology, Inc.
Peripheral T Cell Lymphoma
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)
It is a multi-center, prospective, open-label, two-stage optimized design, single-arm, phase II clinical study to evaluate the efficacy and safety of GB226 for the treatment of relapsed and refractory peripheral T cell lymphoma…
- Trial name
- NCT03502629
- Testing
- GB226
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Genor Biopharma Co., Ltd.
Maintenance Treatment of Peripheral T-cell Lymphoma
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
This is a multicenter, randomized, double-blind, placebo-controlled phase III trial evaluating golidocitinib as maintenance therapy in adult patients with peripheral T-cell lymphoma (PTCL) who achieved complete response (CR) or…
- Trial name
- T-START-M1 (NCT07300514)
- Testing
- PET-CTandct- DNAdetection, golidocitinib
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Fudan University
Peripheral T-cell Lymphoma
The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)
1. Primary Research Question What are the rates of complete response (CR), partial response (PR), progression free survival (PFS) and overall survival (OS) in adult patients newly diagnosed with Peripheral T-Cell Lymphoma (PTCL)…
- Trial name
- C+CHOP/ESHAP (NCT00930605)
- Testing
- CHOP regimen alternate with ESHAP regimen, Alemtuzumab
- Where
- Thailand
- Volunteers
- 16 people
- Sponsor
- King Chulalongkorn Memorial Hospital
Relapsed/Refractory Peripheral T-cell Lymphoma
Chi-GVM Regimen for the Treatment of R/R PTCL
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoproliferative diseases caused by mature T cells, accounting for approximately 10% of non-Hodgkin lymphomas (NHL).
- Trial name
- NCT06211881
- Testing
- Chi-GVM
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lymphoma, Malignant, Non-hodgkin Lymphoma
DS-3201b in Participants With Lymphomas
DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to…
- Trial name
- NCT02732275
- Testing
- DS-3201b
- Where
- 20 sites in United States, Japan
- Volunteers
- 100 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Peripheral T-Cell Lymphoma
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
This study examines the use of denileukin diftitox (Ontak) for patients with peripheral T-cell lymphoma who are candidates for autologous stem cell transplants.
- Trial name
- NCT00632827
- Testing
- Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco